Loading...
•
Sep 30, 2024
Nkarta Q3 2024 Earnings Report
Reported financial results for the third quarter ended September 30, 2024.
Key Takeaways
Nkarta reported a cash balance of $405.3 million as of September 30, 2024, which is expected to fund operations into late 2027. The company is prioritizing the advancement of NKX019 for multiple autoimmune diseases and forgoing further development of NKX019 in lymphoma.
First patient dosed in each of Ntrust-1 and investigator-sponsored clinical trial (IST) of NKX019; enrollment ongoing in both studies
Enrollment in Ntrust-2 expected to initiate by year-end 2024
Preliminary clinical data from Ntrust-1 and Ntrust-2 clinical trials planned for 2025
Platform prioritized to focus on advancement of NKX019 for multiple autoimmune diseases
Forward Guidance
Nkarta expects its current cash and cash equivalents will be sufficient to fund its current operating plan into late 2027.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...